JP2016507532A5 - - Google Patents

Download PDF

Info

Publication number
JP2016507532A5
JP2016507532A5 JP2015556343A JP2015556343A JP2016507532A5 JP 2016507532 A5 JP2016507532 A5 JP 2016507532A5 JP 2015556343 A JP2015556343 A JP 2015556343A JP 2015556343 A JP2015556343 A JP 2015556343A JP 2016507532 A5 JP2016507532 A5 JP 2016507532A5
Authority
JP
Japan
Prior art keywords
staphylococcus
subspecies
subject
streptococcus
bacillus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015556343A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016507532A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2014/000101 external-priority patent/WO2014121342A1/en
Publication of JP2016507532A publication Critical patent/JP2016507532A/ja
Publication of JP2016507532A5 publication Critical patent/JP2016507532A5/ja
Pending legal-status Critical Current

Links

Images

JP2015556343A 2013-02-08 2014-02-10 局所微生物感染を処置する方法 Pending JP2016507532A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2013900412 2013-02-08
AU2013900412A AU2013900412A0 (en) 2013-02-08 Methods Of Treating Microbial Infections, Including Skin Infections
PCT/AU2014/000101 WO2014121342A1 (en) 2013-02-08 2014-02-10 Methods of treating topical microbial infections

Publications (2)

Publication Number Publication Date
JP2016507532A JP2016507532A (ja) 2016-03-10
JP2016507532A5 true JP2016507532A5 (enExample) 2017-03-16

Family

ID=51299090

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015556343A Pending JP2016507532A (ja) 2013-02-08 2014-02-10 局所微生物感染を処置する方法

Country Status (10)

Country Link
US (1) US9943500B2 (enExample)
EP (1) EP2953623B1 (enExample)
JP (1) JP2016507532A (enExample)
KR (1) KR20150119007A (enExample)
CN (3) CN113144197A (enExample)
AU (1) AU2014214547B2 (enExample)
CA (1) CA2900372C (enExample)
MX (1) MX359921B (enExample)
RU (1) RU2675360C2 (enExample)
WO (1) WO2014121342A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3967312A1 (en) 2014-09-12 2022-03-16 UNION therapeutics A/S Antibacterial use of halogenated salicylanilides
TWI656872B (zh) * 2014-11-13 2019-04-21 美商益農美國公司 甲基鹽黴素於豬飼料中之抗病毒效果
GB201509326D0 (en) 2015-05-29 2015-07-15 Antibio Tx Aps Novel use
CN105218562A (zh) * 2015-09-30 2016-01-06 浙江汇能动物药品有限公司 一种d(-)-磺苄西林钠的制备方法
CN109789125B (zh) * 2016-08-16 2022-10-18 罗切斯特大学 含有基于多粘菌素b/甲氧苄啶的治疗剂的药物组合物
BR112018076609B1 (pt) 2016-12-15 2023-02-14 Société des Produits Nestlé S.A. Composição alimentícia para animais de estimação, seus usos, e métodos não terapêutico para modular a quantidade e para medição de uma alteração na quantidade de pelo menos uma dentre bifidobacterium, lactobacillus ou clostridium perfringens
CN106693924B (zh) * 2016-12-16 2019-06-11 昆明理工大学 一种纳米二氧化硅吸附剂、制备方法及其应用
CN106943349B (zh) * 2017-04-21 2020-12-11 华南农业大学 一种泰地罗新混悬注射液及其制备方法
IT201700060645A1 (it) * 2017-06-01 2018-12-01 Abiogen Pharma Spa Uso di xibornolo come agente attivo nel trattamento dell’acne volgare
CN108977481B (zh) * 2017-11-08 2021-08-27 北大方正集团有限公司 一种发酵生产麦白霉素的方法
CN108165511B (zh) * 2018-01-22 2020-11-20 四川农业大学 一种筛选培养基及制备方法和应用与微生物的筛选培养方法
CN108403676B (zh) * 2018-03-20 2020-08-21 中山大学 琥珀酸在提高细菌对抗生素敏感性方面的应用
CN108663463A (zh) * 2018-08-16 2018-10-16 齐鲁动物保健品有限公司 一种泰地罗新的含量检测方法
US11318149B2 (en) * 2018-09-27 2022-05-03 Board Of Trustees Of Michigan State University Compositions and methods for inhibiting biofilm-forming bacteria
CN111195246A (zh) * 2018-11-16 2020-05-26 广西医科大学 聚醚类抗生素k-41b、k-41a在制备治疗或预防艾滋病毒药物中的应用
CN109452294B (zh) * 2018-12-05 2022-05-17 北京市农林科学院 一种防控瓜类细菌性果斑病的方法及其专用种子杀菌剂
AU2019397458A1 (en) * 2018-12-11 2021-06-17 Glyciome, Llc Topical, isotonic compositions for genital use
US11419834B2 (en) 2019-02-25 2022-08-23 Rhode Island Hospital Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide
CN109806273B (zh) * 2019-03-05 2021-07-02 艾美科健（中国）生物医药有限公司 泰拉霉素和加米霉素的复合溶液剂及其制备方法与应用
EP3946547A4 (en) 2019-03-26 2023-01-18 Pocket Naloxone Corp. DEVICES AND METHODS FOR DELIVERING PHARMACEUTICAL COMPOSITIONS
MX2021012865A (es) * 2019-04-24 2021-12-10 Unilever Ip Holdings B V Composiciones antimicrobianas.
CN110172524B (zh) * 2019-06-05 2021-06-11 华中农业大学 制定鸡产气荚膜梭菌对阿维拉霉素的耐药判定标准的方法
CN110128486B (zh) * 2019-06-19 2022-12-02 常州齐晖药业有限公司 一种泰拉霉素的合成方法
CN110372729B (zh) * 2019-08-06 2022-03-22 泊诺(天津)创新医药研究有限公司 一种氟氧头孢钠的精制方法
CN110865134A (zh) * 2019-10-22 2020-03-06 河北远征药业有限公司 一种泰地罗新含量检测方法
CN111150876B (zh) * 2020-01-06 2020-12-01 中国科学院长春应用化学研究所 耐药性可视化的创可贴及其制备方法
CA3180160A1 (en) * 2020-04-17 2021-10-21 Shenzhen Pharmacin Co., Ltd Pharmaceutical compositions
CN113813283B (zh) * 2020-06-19 2023-12-12 中山大学附属第六医院 一类化合物促皮肤损伤修复的用途
US11278709B1 (en) 2021-03-12 2022-03-22 Pocket Naloxone Corp. Drug delivery device and methods for using same
CN113318107B (zh) * 2021-07-08 2022-07-12 中国科学院微生物研究所 一种含氮化合物在制备抗真菌药物中的应用
CN113712988A (zh) * 2021-08-17 2021-11-30 塔里木大学 一种槲皮素-替米考星聚合物纳米微粒、其制备方法及应用
CN113975373A (zh) * 2021-11-18 2022-01-28 宁波市眼科医院 眼用制剂
CN119291073B (zh) * 2024-11-05 2025-05-13 兰州大学第二医院 一种同时检测多黏菌素和卡泊芬净含量的方法、内标物的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2171966B1 (enExample) * 1972-02-17 1975-03-14 Pierrefitte Auby Sa
US3873693A (en) 1974-03-11 1975-03-25 Squibb & Sons Inc Ionomycin
EP0200508B1 (en) * 1985-04-27 1991-10-02 Nitto Denko Corporation Adhesive oral bandages and oral pharmaceutical preparations
BG45570A1 (en) 1987-06-11 1989-07-14 Stefan G Dundarov Means for virus desease cure
US5130139A (en) * 1990-07-06 1992-07-14 Alza Corporation Reduction or prevention of skin irritation by drugs
CN1109757A (zh) * 1995-01-26 1995-10-11 广西壮族自治区容县生物化学工程公司 抗家禽球虫病组合物及其制备方法
AU720243B2 (en) * 1996-06-20 2000-05-25 Novartis Ag Method for the prevention and treatment of mastitis
US7223416B2 (en) * 1999-06-28 2007-05-29 Minu, L.L.C. Topical composition
EP1086947A1 (en) * 1999-09-01 2001-03-28 Pfizer Products Inc. Somatostatin antagonists and agonists that act at the SST subtype 2 receptor
DE60026350T2 (de) * 1999-11-12 2006-11-09 Merck & Co., Inc. Diaryl piperidyl-pyrrol-derivate als antiprotozoenmittel
AU2003218279A1 (en) * 2002-04-22 2003-11-03 The Procter & Gamble Company Use of materials having zinc ionophoric behavior
US20060194769A1 (en) 2005-01-25 2006-08-31 University Of Vermont And State Agricultural College Small molecules that reduce fungal growth
WO2008075207A2 (en) * 2006-04-04 2008-06-26 Foamix Ltd. Anti-infection augmentation foamable compositions and kit and uses thereof
GB0709513D0 (en) * 2007-05-17 2007-06-27 Helperby Therapeutics Ltd Topical formulations
US20120101056A1 (en) * 2009-04-13 2012-04-26 Apex Laboratories Private Limited Medicinal Cream Made Using Framycetin Sulphate and Chitosan and a Process to Make the Same
BRPI1002601E2 (pt) * 2010-06-01 2020-06-30 Embrapa Pesquisa Agropecuaria composição nanoestruturada de uso veterinário para administração de fármacos
AU2013344879B2 (en) * 2012-11-13 2016-04-28 Nant Holdings Ip, Llc Calcium flux agonists and methods therefor

Similar Documents

Publication Publication Date Title
JP2016507532A5 (enExample)
JP2016507533A5 (enExample)
Gao et al. Quinolone derivatives and their activities against methicillin-resistant Staphylococcus aureus (MRSA)
Sharpe et al. Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus
JP2013155188A5 (enExample)
WO2013123215A3 (en) Antiviral drugs for treatment of arenavirus infection
UA96964C2 (ru) Соединения полициклической мочевины с антибактериальными свойствами
BR0307898A (pt) Formulações de droga antibiótica oftálmica contendo um composto de ciclodextrina e cloreto de cetil piridìnio
MX2021004546A (es) Composiciones de suministro de farmaco implantables y metodos de uso de las mismas.
BR112017027811A2 (pt) conjugados específicos de inibidores de ksp
CN111479566A (zh) 用于治疗病毒和细菌感染的新mek抑制剂
JP2017519730A5 (enExample)
BR112015030315A2 (pt) derivado de 4-alquinilimidazol e medicamento compreendendo o mesmo como ingrediente ativo
MX2013004099A (es) Conjunto de juguete de construccion.
MX2013004394A (es) Composicion farmaceutica topica de mupirocina.
MY184630A (en) Tylosin derivatives and method for preparation thereof
WO2016004216A3 (en) Hydrogels for treating and ameliorating infections and methods of making and using them
JP2018521143A5 (enExample)
KR20180051622A (ko) 항생물질 요법
Hussain et al. Successful treatment of meticillin-resistant Staphylococcus aureus bacteraemia in a neonate using daptomycin
Albareda et al. A randomized vehicle-controlled trial to assess the efficacy, safety, and tolerability of ozenoxacin 1% cream in 412 patients 2 months and older with impetigo
EA201590350A1 (ru) Комбинации с пептидом с циклизованной основной цепью
WO2009124086A3 (en) Antibacterial drug for treatment of staphylococcus aureus and other gram-positive bacterial infections
Petrunin Microbiome of human skin-its immunohomeostatic role and the role in pathogenesis of skin diseases
Kalenić The importance of methicillin-resistant Staphylococcus aureus in human medicine